ISpecimen Operating Income Over Time
| ISPC Stock | USD 0.25 0.03 10.71% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out ISpecimen Performance and ISpecimen Correlation. ISpecimen | Build AI portfolio with ISpecimen Stock |
Will Biotechnology sector continue expanding? Could ISpecimen diversify its offerings? Factors like these will boost the valuation of ISpecimen. Market participants price ISpecimen higher when confident in its future expansion prospects. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every ISpecimen data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (7.82) | Revenue Per Share | Quarterly Revenue Growth (0.96) | Return On Assets | Return On Equity |
The market value of iSpecimen is measured differently than its book value, which is the value of ISpecimen that is recorded on the company's balance sheet. Investors also form their own opinion of ISpecimen's value that differs from its market value or its book value, called intrinsic value, which is ISpecimen's true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because ISpecimen's market value can be influenced by many factors that don't directly affect ISpecimen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ISpecimen's value and its price as these two are different measures arrived at by different means. Investors typically determine if ISpecimen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Meanwhile, ISpecimen's quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Cross Equities Operating Income Analysis
Compare iSpecimen and related stocks such as ENDRA Life Sciences, Theriva Biologics, and Catheter Precision Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NDRA | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.5 M) | (1.6 M) | (1.8 M) | (4.6 M) | (9 M) | (10.8 M) | (11.5 M) | (11.5 M) | (13.2 M) | (10.5 M) | (10.8 M) | (9.7 M) | (10.2 M) |
| TOVX | (3.4 M) | (5.9 M) | (17.3 M) | (12.3 M) | (20.5 M) | (41 M) | (39.3 M) | (26.3 M) | (17.6 M) | (15.7 M) | (10.2 M) | (14.3 M) | (21.6 M) | (21.4 M) | (26.3 M) | (23.7 M) | (22.5 M) |
| VTAK | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (4.2 M) | (17.8 M) | (31.2 M) | (57.7 M) | (36.1 M) | (29.3 M) | (27 M) | (78.1 M) | (11.2 M) | (10.1 M) | (10.6 M) |
| HSCS | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (3.8 M) | (2.6 M) | (4.7 M) | (6.1 M) | (6.3 M) | (8.4 M) | (7.5 M) | (7.9 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (14.6 M) | (9.1 M) | (10.9 M) | (16.9 M) | (12.4 M) | (10.7 M) | (22.4 M) | (30.2 M) | (32.9 M) | (17.7 M) | 7.5 M | (6.3 M) | (5.7 M) | (5.9 M) |
| BJDX | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.6 M) | (1.2 M) | (3.2 M) | (9.3 M) | (10.3 M) | (7.2 M) | (6.5 M) | (6.8 M) |
| BIVI | (70.1 K) | (70.1 K) | (70.1 K) | (322.4 K) | (233.4 K) | (432 K) | (1.6 M) | (2.4 M) | (2.5 M) | (2.7 M) | (138.1 M) | (27.3 M) | (45.1 M) | (32.2 M) | (18.1 M) | (16.3 M) | (17.1 M) |
| BIAF | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (3.1 M) | (2.6 M) | (2.2 M) | (4 M) | (8 M) | (9 M) | (8.1 M) | (7.7 M) |
| SHPH | (203.9 K) | (203.9 K) | (203.9 K) | (203.9 K) | (203.9 K) | (203.9 K) | (203.9 K) | (203.9 K) | (586.6 K) | (509.5 K) | (509.5 K) | (1.7 M) | (2.3 M) | (5.9 M) | (7.7 M) | (6.9 M) | (6.6 M) |
| ZCMD | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 1 M | 3.3 M | 3.6 M | 4.5 M | (320.7 K) | (3 M) | (13.3 M) | (341.3 K) | (307.1 K) | (322.5 K) |
iSpecimen and related stocks such as ENDRA Life Sciences, Theriva Biologics, and Catheter Precision Operating Income description
Operating Income is the amount of profit realized from iSpecimen operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of iSpecimen is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| iSpecimen | ISPC |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 8 Cabot Road, |
| Exchange | NASDAQ Exchange |
USD 0.25
Check out ISpecimen Performance and ISpecimen Correlation. For information on how to trade ISpecimen Stock refer to our How to Trade ISpecimen Stock guide.You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.
ISpecimen technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.